GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Medipal Holdings Corp (TSE:7459) » Definitions » Debt-to-EBITDA

Medipal Holdings (TSE:7459) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Medipal Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medipal Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円0 Mil. Medipal Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円0 Mil. Medipal Holdings's annualized EBITDA for the quarter that ended in Dec. 2023 was 円97,848 Mil. Medipal Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Medipal Holdings's Debt-to-EBITDA or its related term are showing as below:

During the past 13 years, the highest Debt-to-EBITDA Ratio of Medipal Holdings was 0.71. The lowest was 0.00. And the median was 0.47.

TSE:7459's Debt-to-EBITDA is not ranked *
in the Medical Distribution industry.
Industry Median: 2
* Ranked among companies with meaningful Debt-to-EBITDA only.

Medipal Holdings Debt-to-EBITDA Historical Data

The historical data trend for Medipal Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medipal Holdings Debt-to-EBITDA Chart

Medipal Holdings Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 0.48 0.42 - -

Medipal Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Medipal Holdings's Debt-to-EBITDA

For the Medical Distribution subindustry, Medipal Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medipal Holdings's Debt-to-EBITDA Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Medipal Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Medipal Holdings's Debt-to-EBITDA falls into.



Medipal Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medipal Holdings's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Medipal Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Medipal Holdings  (TSE:7459) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Medipal Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Medipal Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Medipal Holdings (TSE:7459) Business Description

Traded in Other Exchanges
Address
2-7-15, Yaesu, Chuo-ku, Tokyo, JPN, 104-8461
Medipal Holdings Corp distributes pharmaceuticals and health and beauty products to medical institutions and retailers. The firm operates in three segments: prescription pharmaceutical wholesale; cosmetics, daily necessities, and OTC pharmaceutical wholesale; and animal health products wholesale. The prescription pharmaceutical business generates the majority of revenue and distributes products to hospitals, clinics, and pharmacies. The cosmetics, daily necessities, and OTC pharmaceutical businesses distribute products to drugstores, convenience stores, and supermarkets. The animal health segment conducts wholesale business for animal hospitals, farms, and agricultural cooperatives. Medipal Holdings generates the vast majority of its revenue in Japan.

Medipal Holdings (TSE:7459) Headlines

No Headlines